Nykredit A S Purchases New Shares in Bristol Myers Squibb Company $BMY

Key Points

• Nykredit A/S purchased 506,199 Bristol Myers Squibb shares in the second quarter, valued at approximately $29.2 million. Hedge funds and other institutional investors collectively own 76.41% of BMY.
• Bristol Myers Squibb reported quarterly EPS of $2.04, beating estimates of $1.60, while revenue rose 5.7% year over year to $12.97 billion. The company also pays a quarterly dividend of $0.63 per share, equivalent to a 3.7% annualized yield.
• Investor sentiment is mixed: positive Camzyos data and improving momentum support the stock, but the pause in zola-cel autoimmune trials over inflammatory side effects presents pipeline risk. Analysts overall rate BMY a Moderate Buy, with an average price target of $66.06.

Nykredit A S bought a new position in Bristol Myers Squibb Company (NYSE:BMY - Free Report) during the second quarter, according to its most recent 13F filing with the SEC. The fund bought 506,199 shares of the biopharmaceutical company's stock, valued at approximately $29,167,000.

Several other hedge funds have also recently made changes to their positions in BMY. Swiss RE Ltd. purchased a new stake in shares of Bristol Myers Squibb in the fourth quarter worth approximately $25,000. Darwin Wealth Management LLC purchased a new position in Bristol Myers Squibb during the 2nd quarter valued at $25,000. Davis Asset Management L.P. purchased a new position in Bristol Myers Squibb during the 2nd quarter valued at $27,000. Bayban purchased a new stake in Bristol Myers Squibb in the fourth quarter worth $31,000. Finally, Addison Advisors LLC purchased a new stake in Bristol Myers Squibb in the second quarter worth $32,000. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

More Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Encouraging long-term data for Camzyos from the EXPLORER-LTE study supported renewed investor interest in the heart-failure drug. The data add to expectations that Camzyos can remain an important growth product for Bristol Myers Squibb. Bristol Myers Squibb Gains on Camzyos Data
• Positive Sentiment: Analysts and market commentators highlighted bullish technical indicators, strong recent returns, and Bristol Myers Squibb’s outperformance versus the broader healthcare sector. These factors may be attracting momentum-oriented investors. Revisiting Stock Picks
• Neutral Sentiment: RBC Capital maintained a Hold rating, reflecting a balanced view: BMY’s valuation and improving business momentum are constructive, but the stock’s strong run may already incorporate much of the favorable news. RBC Capital Maintains Hold Rating
• Negative Sentiment: Bristol Myers Squibb voluntarily paused enrollment in its zola-cel autoimmune cell-therapy trials after inflammatory side effects emerged during safety monitoring. The pause raises concerns about the therapy’s risk profile, delays a potentially important pipeline program, and may increase scrutiny of trial-disclosure practices. What Does the BMY Trial Pause Mean for Its Pipeline?
• Negative Sentiment: Broader reporting that Novartis and Bristol Myers Squibb halted autoimmune trials following deaths or serious side effects reinforces concerns about the safety and development risk of experimental cell therapies. Drugmakers Halt Autoimmune Trials

Bristol Myers Squibb Price Performance

Shares of BMY stock opened at $68.06 on Friday. Bristol Myers Squibb Company has a twelve month low of $42.52 and a twelve month high of $68.64. The company has a current ratio of 1.53, a quick ratio of 1.38 and a debt-to-equity ratio of 1.89. The stock has a fifty day simple moving average of $62.73 and a two-hundred day simple moving average of $59.87. The stock has a market capitalization of $139.03 billion, a price-to-earnings ratio of 14.99, a P/E/G ratio of 0.32 and a beta of 0.23.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, beating the consensus estimate of $1.60 by $0.44. The firm had revenue of $12.97 billion for the quarter, compared to analyst estimates of $11.74 billion. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.The business's revenue for the quarter was up 5.7% on a year-over-year basis. During the same quarter last year, the firm posted $1.46 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. On average, analysts predict that Bristol Myers Squibb Company will post 6.95 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd were given a dividend of $0.63 per share. The ex-dividend date of this dividend was Thursday, July 2nd. This represents a $2.52 dividend on an annualized basis and a yield of 3.7%. Bristol Myers Squibb's dividend payout ratio (DPR) is 55.51%.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on BMY shares. Sanford C. Bernstein raised shares of Bristol Myers Squibb from a "market perform" rating to an "outperform" rating in a research note on Wednesday, August 5th. Raymond James Financial began coverage on shares of Bristol Myers Squibb in a research note on Wednesday, August 5th. They issued a "strong-buy" rating on the stock. Piper Sandler initiated coverage on shares of Bristol Myers Squibb in a report on Wednesday, August 5th. They set an "overweight" rating for the company. Jefferies Financial Group cut shares of Bristol Myers Squibb from a "buy" rating to a "hold" rating in a research report on Wednesday, August 5th. Finally, BMO Capital Markets restated a "market perform" rating on shares of Bristol Myers Squibb in a research note on Monday, July 27th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $66.06.

Insider Activity at Bristol Myers Squibb

In other news, SVP Phil M. Holzer sold 500 shares of the company's stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total value of $33,750.00. Following the completion of the sale, the senior vice president owned 16,862 shares of the company's stock, valued at approximately $1,138,185. This represents a 2.88% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.05% of the company's stock.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source